Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vial per carton, Rx Only, Novaplus, Manufactured...
FDA Drug Recall #D-1309-2022 — Class II — July 11, 2022
Recall Summary
| Recall Number | D-1309-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 11, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Hikma Pharmaceuticals USA Inc. |
| Location | Cherry Hill, NJ |
| Product Type | Drugs |
| Quantity | 713,550 vials |
Product Description
Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vial per carton, Rx Only, Novaplus, Manufactured by Hikma Berkeley Heights, NJ 07922. Carton NDC# 0641-6048-25, Vial NDC# 0641-6048-01
Reason for Recall
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot # 070088, exp. date 07/2023
Other Recalls from Hikma Pharmaceuticals USA Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0551-2025 | Class II | Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL via... | Jul 22, 2025 |
| D-0635-2024 | Class I | Acetaminophen Injection, 1,000 mg per 100 mL (1... | Jul 8, 2024 |
| D-0392-2024 | Class II | Infumorph (Preservative-free Morphine Sulfate S... | Mar 12, 2024 |
| D-0574-2023 | Class II | Lorazepam Injection, USP, 2mg/mL, 1 mL vial (ND... | May 11, 2023 |
| D-0090-2023 | Class II | Ganciclovir for Injection, USP, 500mg per vial,... | Dec 16, 2022 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.